

Phone: 1-800-809-1265 Fax: 1-866-872-8920

REQUIRED: TB screening for new start patients

HBV screening/labs as required by payor

| Referral Status: | M | RN: |
|---------------------------|--------------|---------------|
| New referral | Order change | Order Renewal |
| Patient preferred clinic: | | |

Continue current order until insurance approved

Cimzia® (certolizumab pegol) Standard Plan of Treatment for Rheumatology & Dermatology

| PATIENT DEMOGRAPHICS: | | | | | | | | | |
|-----------------------|---------|-------|----------|-------------------|---|------------|--|----------|------|
| Date of Referral: | | | | Patient's Phone: | | | | | |
| Patient Name: | | | Address: | | | | | | |
| Date of Birth: | | | | City, State, Zip: | | | | | |
| Height in inches: | Weight: | LB or | KG | Gender: | / | Allergies: | | See list | NDKA |
| | | | | | | | | | |

| DIAGNOSIS: (PLEASE COMPLETE 2 ND AND 3 RD DIGITS TO COMPLETE ICD 10 FOR BILLING) | | | | | | | |
|---|--|------------------|--|--|--|--|--|
| | M05 Rheumatoid Arthritis with rheumatoid factor | | M45.A Non-radiographic axial spondyloarthritis | | | | |
| | M06 Rheumatoid Arthritis without rheuma | atoid factor | L40.0 - Psoriasis vulgaris | | | | |
| | M45 Ankylosing Spondylitis | | L40.5 Arthropathic psoriasis | | | | |
| | M46.8 Other specified inflammatory spondy | ylopathies | L40.9 - Psoriasis, unspecifed | | | | |
| | Other: | | | | | | |
| REQ | REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE? | | | | | | |
| 1 | Insurance information | IF NO: | IF YES: | | | | |
| 2 | Most recent History & Physical | | LAST INJECTION DATE: | | | | |
| 3 | Full medication list | REQUIRED WASHOUT | NEXT INJECTION DATE: | | | | |
| 4 | Tried and failed therapies | THERAPY: | IF ORDER CHANGE: | | | | |

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive certolizumab pegol if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening symptoms of CHF, new-onset or deterioration neurological changes, and/or surgery.

DOSE/FREQUENCY:

Induction: Cimzia[®] (certolizumab pegol) 400mg at week 0, week 2, week 4, and maintenance as indicated below Maintenance: Cimzia[®] (certolizumab pegol) 200mg every 2 weeks

Maintenance: Cimzia[®] (certolizumab pegol) 400mg every 4 weeks

Administer as 2 divided subcutaneous injections to separate sites in the abdomen or thigh only

SPECIAL ORDERS:

5

6

Prescriber confirms that the patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment. Prescriber to monitor patient for symptoms of HBV and TB infection and reactivation as clinically appropriate.

Refills x 12 months unless noted otherwise here:

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



| PRESCRIBER INFORMATION: | | | | | | |
|---|------|--------|-------------------|------|--|--|
| PROVIDER NAME: | | PHONE: | | | | |
| ADDRESS: | | FAX: | | | | |
| CITY, STATE, ZIP: | NPI: | | | | | |
| PRESCRIBER SIGNATURE: (No stamp signatures) | | | | DATE | | |
| | | | | | | |
| | | | | | | |
| Dispense as written/Brand medically necessary | | Subst | itution permitted | | | |